The Bear Case For Bionano Genomics Carries More Weight

105
31
Favorite

The Bear Case For Bionano Genomics Carries More Weight

InvestorPlace2021-06-07

BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

105

Report

Comment（31）

Meshaarias72
·2021-06-07
Like n comment pls
Reply
Like
Report
Sysy
·2021-06-07
Huat
Reply
1
Report
Fold Replies
- Meshaarias72:
  Yes
  2021-06-07
  Reply
  Report
Bll
·2021-06-07
Good news
Reply
3
Report
Fold Replies
- Meshaarias72:
  Yes
  2021-06-07
  Reply
  Report
PREM
·2021-06-07
Any guess Short term target?
Reply
Like
Report
b1gman
·2021-06-07
pls help!:D
Reply
3
Report
KW1
·2021-06-07
Great. Buy bngo
Reply
3
Report
JasonHong
·2021-06-07
Please Help to Like & Comment to me
Reply
2
Report
Fold Replies
- b1gman:
  help too
  2021-06-07
  Reply
  Report
Kendaman
·2021-06-07
Huat ah
Reply
3
Report
Vivienrose
·2021-06-07
Hi please me reply thank u
Reply
3
Report
Fold Replies
- SCP03:
  replied...dunno why the translation
  2021-06-07
  Reply
  Report
- SCP03:
  there u go!
  2021-06-07
  Reply
  Report
Juelo
·2021-06-07
yay
Reply
4
Report
Phoenix5104
·2021-06-07
Holding on and going strong!Please like and comment too!
Reply
3
Report
Fold Replies
- ALi_BaBa:
  Great
  2021-06-07
  Reply
  Report
zhangming
·2021-06-07
AMC TO THE MOON!
Reply
5
Report
iamateh
·2021-06-07
like and comment pls!!
Reply
5
Report
Fold Replies
- zhangming:
  AMC TO THE MOON!
  2021-06-07
  Reply
  Report
- Ryacleigh:
  Nice
  2021-06-07
  Reply
  Report
WannWah
·2021-06-07
Like and share
Reply
6
Report
HappyTrade
·2021-06-07
Looking forward to double digit soon..... [財迷]
Reply
3
Report
HappyTrade
·2021-06-07
Waiting for double digit again....hopefully soon[財迷]
Reply
4
Report
Sucrammis
·2021-06-07
[Cool]
Reply
5
Report
WayneSing
·2021-06-07
comment and like thanks
Reply
3
Report
Fold Replies
- Pettan:
  We will profits?
  2021-06-08
  Reply
  Report
- Pettan:
  Nice, thanks ?
  2021-06-07
  Reply
  Report
- zhen130:
  Pls reply too
  2021-06-07
  Reply
  Report
View more 2 comments
dar
·2021-06-07
Wow
Reply
4
Report
Fold Replies
- Wellyanto:
  Done
  2021-06-07
  Reply
  Report
- WayneSing:
  return my comment and like thanks
  2021-06-07
  Reply
  Report
MagPie
·2021-06-07
Time to observe whether it will break through the resistance
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1112319097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-07 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112319097","market":"us","top_or_hot":-1,"title":"The Bear Case For Bionano Genomics Carries More Weight","media":"InvestorPlace","content":"<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","article_id":"1112319097","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","pubTimestamp":1623055213,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"Bionano基因组学的熊案例更有分量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":0.9},"content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":114697201,"gmtCreate":1623071209103,"gmtModify":1704195412541,"author":{"id":"3577781617271173","authorId":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114697201","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114845765,"gmtCreate":1623069246857,"gmtModify":1704195369568,"author":{"id":"3581726174893746","authorId":"3581726174893746","name":"Sysy","avatar":"https://static.tigerbbs.com/f89400ba2f20ed80423858c0f6a3d8ee","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114845765","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4617520,"gmtCreate":1623071228998,"gmtModify":1663228127853,"authorId":3577781617271173,"author":{"id":3577781617271173,"authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114845765,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":114895628,"gmtCreate":1623063693264,"gmtModify":1704195275866,"author":{"id":"3575152525326279","authorId":"3575152525326279","name":"Bll","avatar":"https://static.tigerbbs.com/b372fc92d67296f5ba36af78d1d6e935","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114895628","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4617525,"gmtCreate":1623071235879,"gmtModify":1663228130049,"authorId":3577781617271173,"author":{"id":3577781617271173,"authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114895628,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":114807193,"gmtCreate":1623062962912,"gmtModify":1704195265065,"author":{"id":"3583719080393906","authorId":"3583719080393906","name":"PREM","avatar":"https://static.tigerbbs.com/bd4e9099a744c8af75ebaa2e0ce2f09b","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Any guess Short term target?&nbsp;","listText":"Any guess Short term target?&nbsp;","text":"Any guess Short term target?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114807193","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114171287,"gmtCreate":1623061205449,"gmtModify":1704195242915,"author":{"id":"3583748261189325","authorId":"3583748261189325","name":"b1gman","avatar":"https://static.tigerbbs.com/6a1489bd78edf55795eddbec4fca6280","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"pls help!:D","listText":"pls help!:D","text":"pls help!:D","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114171287","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114147916,"gmtCreate":1623060859135,"gmtModify":1704195236881,"author":{"id":"3563714281601583","authorId":"3563714281601583","name":"KW1","avatar":"https://static.tigerbbs.com/094e3f8fd8b3de3da976515926ed1403","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1},"htmlText":"Great. Buy bngo","listText":"Great. Buy bngo","text":"Great. Buy bngo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114147916","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114147011,"gmtCreate":1623060852633,"gmtModify":1704195236532,"author":{"id":"3585283371231222","authorId":"3585283371231222","name":"JasonHong","avatar":"https://static.tigerbbs.com/345cd76b2eec5d1915f3852276dd4d45","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Please Help to Like &amp; Comment to me","listText":"Please Help to Like &amp; Comment to me","text":"Please Help to Like & Comment to me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114147011","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615940,"gmtCreate":1623062674062,"gmtModify":1663228121238,"authorId":3583748261189325,"author":{"id":3583748261189325,"authorId":3583748261189325,"name":"b1gman","avatar":"https://static.tigerbbs.com/6a1489bd78edf55795eddbec4fca6280","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114147011,"type":1,"supId":0,"prevId":0,"content":"help too","text":"help too","html":"help too"}],"langContent":"EN"},{"id":114156935,"gmtCreate":1623059545927,"gmtModify":1704195217291,"author":{"id":"3578003575720363","authorId":"3578003575720363","name":"Kendaman","avatar":"https://static.tigerbbs.com/ede8fd0a4f53700b144284ba889b0719","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114156935","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114159207,"gmtCreate":1623059385309,"gmtModify":1704195212530,"author":{"id":"3575585519231161","authorId":"3575585519231161","name":"Vivienrose","avatar":"https://static.tigerbbs.com/def4c9c09d2d61a66e1bd9447e42aa29","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hi please me reply thank u","listText":"Hi please me reply thank u","text":"Hi please me reply thank u","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114159207","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615720,"gmtCreate":1623061101679,"gmtModify":1663228119629,"authorId":3561986763872297,"author":{"id":3561986763872297,"authorId":3561986763872297,"name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"currentWearingBadge":{"badgeId":"29815c1501c442c58b708482689df577-1","templateUuid":"29815c1501c442c58b708482689df577","name":"Emerging Contributor","description":"Contributors who received Editor's Pick for the 1st time","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.31","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2005},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114159207,"type":1,"supId":4615718,"prevId":0,"content":"replied...dunno why the translation","text":"replied...dunno why the translation","html":"replied...dunno why the translation"},{"id":4615718,"gmtCreate":1623061078645,"gmtModify":1663228118430,"authorId":3561986763872297,"author":{"id":3561986763872297,"authorId":3561986763872297,"name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"currentWearingBadge":{"badgeId":"29815c1501c442c58b708482689df577-1","templateUuid":"29815c1501c442c58b708482689df577","name":"Emerging Contributor","description":"Contributors who received Editor's Pick for the 1st time","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.31","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2005},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114159207,"type":1,"supId":0,"prevId":0,"content":"there u go!","text":"there u go!","html":"there u go!"}],"langContent":"EN"},{"id":114168499,"gmtCreate":1623058121111,"gmtModify":1704195188215,"author":{"id":"3584151097809421","authorId":"3584151097809421","name":"Juelo","avatar":"https://static.tigerbbs.com/44b1b2a7ad3407d486dd49dd047d2b80","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":6,"crmLevelSwitch":1},"htmlText":"yay","listText":"yay","text":"yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114168499","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114169621,"gmtCreate":1623057858763,"gmtModify":1704195183954,"author":{"id":"3585694968236372","authorId":"3585694968236372","name":"Phoenix5104","avatar":"https://static.tigerbbs.com/f0a316ae2880cadff61373ca7d5cf06a","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Holding on and going strong!Please like and comment too!","listText":"Holding on and going strong!Please like and comment too!","text":"Holding on and going strong!Please like and comment too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114169621","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615287,"gmtCreate":1623058109533,"gmtModify":1663228114849,"authorId":3564105303063302,"author":{"id":3564105303063302,"authorId":3564105303063302,"name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114169621,"type":1,"supId":0,"prevId":0,"content":"Great","text":"Great","html":"Great"}],"langContent":"EN"},{"id":114187954,"gmtCreate":1623057717278,"gmtModify":1704195180523,"author":{"id":"3582333701245743","authorId":"3582333701245743","name":"zhangming","avatar":"https://community-static.tradeup.com/news/952e7023506539855846cdfc155e2969","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"AMC TO THE MOON!","listText":"AMC TO THE MOON!","text":"AMC TO THE MOON!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114187954","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114189486,"gmtCreate":1623057210645,"gmtModify":1704195169578,"author":{"id":"3554804006357295","authorId":"3554804006357295","name":"iamateh","avatar":"https://static.tigerbbs.com/cfa6492594e288f70d24f72146aeec45","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"like and comment pls!!&nbsp;","listText":"like and comment pls!!&nbsp;","text":"like and comment pls!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114189486","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615206,"gmtCreate":1623057727493,"gmtModify":1663228115945,"authorId":3582333701245743,"author":{"id":3582333701245743,"authorId":3582333701245743,"name":"zhangming","avatar":"https://community-static.tradeup.com/news/952e7023506539855846cdfc155e2969","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114189486,"type":1,"supId":0,"prevId":0,"content":"AMC TO THE MOON!","text":"AMC TO THE MOON!","html":"AMC TO THE MOON!"},{"id":4615319,"gmtCreate":1623058332964,"gmtModify":1663228115136,"authorId":3566723689439669,"author":{"id":3566723689439669,"authorId":3566723689439669,"name":"Ryacleigh","avatar":"https://static.tigerbbs.com/99db9b9b2d5d303db43970c31a6ba528","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114189486,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":114111119,"gmtCreate":1623056676431,"gmtModify":1704195156429,"author":{"id":"3581902399516412","authorId":"3581902399516412","name":"WannWah","avatar":"https://static.tigerbbs.com/f999607e2749596598ba5a5db56740c2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and share&nbsp;","listText":"Like and share&nbsp;","text":"Like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114111119","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114110443,"gmtCreate":1623056503282,"gmtModify":1704195153191,"author":{"id":"3561676944889444","authorId":"3561676944889444","name":"HappyTrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Looking forward to double digit soon.....&nbsp;[財迷]&nbsp;","listText":"Looking forward to double digit soon.....&nbsp;[財迷]&nbsp;","text":"Looking forward to double digit soon..... [財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114110443","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":114137632,"gmtCreate":1623056443626,"gmtModify":1704195152220,"author":{"id":"3561676944889444","authorId":"3561676944889444","name":"HappyTrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Waiting for double digit again....hopefully soon[財迷]&nbsp;","listText":"Waiting for double digit again....hopefully soon[財迷]&nbsp;","text":"Waiting for double digit again....hopefully soon[財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114137632","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":114135453,"gmtCreate":1623056360672,"gmtModify":1704195149633,"author":{"id":"3567510698843882","authorId":"3567510698843882","name":"Sucrammis","avatar":"https://static.tigerbbs.com/b53e2d1cd4fdf176174f088adbd03e1c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114135453","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114197120,"gmtCreate":1623055953860,"gmtModify":1704195137635,"author":{"id":"3584427442291849","authorId":"3584427442291849","name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"comment and like thanks","listText":"comment and like thanks","text":"comment and like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/114197120","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4630294,"gmtCreate":1623137906700,"gmtModify":1663228189843,"authorId":3576213741857476,"author":{"id":3576213741857476,"authorId":3576213741857476,"name":"Pettan","avatar":"https://static.tigerbbs.com/eea8055165cc8ba5c3e2968ccdcd6400","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"We will profits?","text":"We will profits?","html":"We will profits?"},{"id":4615791,"gmtCreate":1623061649899,"gmtModify":1663228116727,"authorId":3576213741857476,"author":{"id":3576213741857476,"authorId":3576213741857476,"name":"Pettan","avatar":"https://static.tigerbbs.com/eea8055165cc8ba5c3e2968ccdcd6400","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"Nice, thanks ?","text":"Nice, thanks ?","html":"Nice, thanks ?"},{"id":4614969,"gmtCreate":1623056784335,"gmtModify":1663228116452,"authorId":3570360623104656,"author":{"id":3570360623104656,"authorId":3570360623104656,"name":"zhen130","avatar":"https://static.tigerbbs.com/553509e2e649eaf0d39f267a7e6de1a1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"Pls reply <u>too</u>","text":"Pls reply <u>too</u>","html":"Pls reply <u>too</u>"},{"id":4614806,"gmtCreate":1623056036626,"gmtModify":1663228113651,"authorId":3576213741857476,"author":{"id":3576213741857476,"authorId":3576213741857476,"name":"Pettan","avatar":"https://static.tigerbbs.com/eea8055165cc8ba5c3e2968ccdcd6400","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":0,"prevId":0,"content":"Pls like and comment too ?","text":"Pls like and comment too ?","html":"Pls like and comment too ?"},{"id":4614897,"gmtCreate":1623056481117,"gmtModify":1663228111553,"authorId":3584157211271817,"author":{"id":3584157211271817,"authorId":3584157211271817,"name":"Etet1985","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":114194339,"gmtCreate":1623055871421,"gmtModify":1704195135858,"author":{"id":"3554840164932540","authorId":"3554840164932540","name":"dar","avatar":"https://static.tigerbbs.com/e4bcf35c6c1a9221c5cc6cce74413dff","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114194339","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4617116,"gmtCreate":1623069371097,"gmtModify":1663228126428,"authorId":3578723450181101,"author":{"id":3578723450181101,"authorId":3578723450181101,"name":"Wellyanto","avatar":"https://static.tigerbbs.com/da46836141f0e6c7ed8114362646057a","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.11","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114194339,"type":1,"supId":4614787,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":4614787,"gmtCreate":1623055976507,"gmtModify":1663228113755,"authorId":3584427442291849,"author":{"id":3584427442291849,"authorId":3584427442291849,"name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114194339,"type":1,"supId":0,"prevId":0,"content":"return my comment and like thanks","text":"return my comment and like thanks","html":"return my comment and like thanks"}],"langContent":"EN"},{"id":114195858,"gmtCreate":1623055814374,"gmtModify":1704195134808,"author":{"id":"3573728905231423","authorId":"3573728905231423","name":"MagPie","avatar":"https://static.tigerbbs.com/86bf766e96cabebb79ece6877432d5da","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Time to observe whether it will break through the resistance","listText":"Time to observe whether it will break through the resistance","text":"Time to observe whether it will break through the resistance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114195858","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":31,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}